A fourth-quarter rebound helped push imaging devices stocks into the black for 1999, according to a survey by HealthCare Markets Group, a Hilton Head, SC-based healthcare advisory and investment banking firm. For the year, imaging devices stocks returned
A fourth-quarter rebound helped push imaging devices stocks into the black for 1999, according to a survey by HealthCare Markets Group, a Hilton Head, SC-based healthcare advisory and investment banking firm. For the year, imaging devices stocks returned an average increase of 3.8%, compared with a 22.9% decrease in 1998, a 9.3% dip in 1997, and a 4.3% increase in 1996. Still, the 1999 performance lagged well behind the 18.7% gain for healthcare industry shares as a whole.
Driving growth in the imaging devices sector was hand-held ultrasound firm SonoSite, which surged 205% during the year, and 3-D software developer Vital Images, which climbed 152%. Digital x-ray developer Swissray rebounded to gain more than 600%, while bone densitometry firm Norland posted a 175% improvement.
Firms experiencing losses for the year included Trex Medical, which dropped 67%, and EndoSonics, which slipped 55%. Hologic also declined 52% in 1999.
In other industry news, imaging services firms found themselves again in the red this year, shedding an average of 10.9% in 1999, compared with a loss of 32.1% in 1998 and a gain of 3.7% in 1997.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.